» Articles » PMID: 32978046

In vitro Antimicrobial and Antipro-inflammation Potential of Honokiol and Magnolol Against Oral Pathogens and Macrophages

Overview
Specialty General Medicine
Date 2020 Sep 26
PMID 32978046
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Background/purpose: Honokiol and magnolol are natural components isolated from Magnolia bark that is used in traditional Chinese and Japanese herbal medicine. These two isomers are used as a component of dietary supplements and cosmetic products. In this study, we investigated the antimicrobial effect of honokiol and magnolol on pathogens causing oral diseases, their mechanism of action in biofilm formation and drug resistance of oral pathogens, and inflammatory regulation in mammalian cells.

Methods: We determined the minimum inhibitory concentration and minimum bactericidal concentration of honokiol and magnolol, and their stability at different temperatures and pH. We also evaluated their effect on biofilm formation, antibiotic-resistance gene expression in MRSA, and pro-inflammatory gene expression in mammalian cells.

Results: Honokiol showed better antimicrobial activity than magnolol. Both honokiol and magnolol showed stable bacterial inhibitory activity over a wide range of temperature and pH, reduced biofilm formation, and antibiotic resistance in oral pathogens. The biofilm formation- and antibiotic resistance-related gene expression was consistent with the respective phenotypes. Furthermore, these two isomers repressed the expression of pro-inflammatory genes in RAW264.7 cells.

Conclusion: Our study provides evidence of the potential application of honokiol and magnolol in dental medicine to cure or prevent oral diseases.

Citing Articles

Polymer-Free Electrospinning of β-Cyclodextrin-Oligolactide for Magnolol and Honokiol Pharmaceutical Formulations.

Blaj D, Peptu C, Balan-Porcarasu M, Peptu C, Tuchilus C, Ochiuz L Pharmaceutics. 2025; 17(1.

PMID: 39861776 PMC: 11768894. DOI: 10.3390/pharmaceutics17010130.


and Evaluation of the Cytotoxic Potential of Hinokitiol against Osteosarcoma by Targeting Glycogen Synthase Kinase 3β.

Cheriyan B, Srinivasan P, Jayaraj G, Karunakar K, Sainath P, Shanmugam A Turk J Pharm Sci. 2025; 21(6):499-505.

PMID: 39801001 PMC: 11730009. DOI: 10.4274/tjps.galenos.2023.65708.


Effect of hinokitiol in ameliorating oral cancer: in vitro and in silico evidences.

Roy A, Cheriyan B, Perumal E, Rengasamy K, Anandakumar S Odontology. 2024; .

PMID: 39540968 DOI: 10.1007/s10266-024-01020-1.


Oral Health and Nutraceutical Agents.

Leo M, DAngeli F, Genovese C, Spila A, Miele C, Ramadan D Int J Mol Sci. 2024; 25(17).

PMID: 39273680 PMC: 11395598. DOI: 10.3390/ijms25179733.


Honokiol alleviates monosodium urate-induced gouty pain by inhibiting voltage-gated proton channels in mice.

Miao L, Yuan Z, Zhang S, Zhang G Inflammopharmacology. 2024; 32(4):2413-2425.

PMID: 38829504 DOI: 10.1007/s10787-024-01498-9.